ロード中...
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well tolerated and showed preliminary antitumor activity in patients with advanced hepatocellular carcinoma. This study aimed to assess the safety, tolerability, and pharmacokinetic...
保存先:
| 出版年: | Cancer Sci |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4317809/ https://ncbi.nlm.nih.gov/pubmed/24521523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12368 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|